Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $26.00 --0%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 19 | New: 29
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 19 | New: 29
Join SI Premium – FREE
Oppenheimer analyst Jay Olson raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $23.00 (from $20.00) while maintaining a Perform rating.
You May Also Be Interested In
- Helen of Troy (HELE) PT Raised to $28 at UBS Following Strong Q1 Results
- Dana Holding (DAN) PT Lowered to $39 at UBS
- Applied Materials (AMAT) PT Raised to $650 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
